Biosensors International Group, Ltd
Jileen Tan is an experienced executive assistant and administrative manager with a robust background in supporting high-level executives across various organizations. Currently serving as the Executive Assistant to the Group CEO and Administrative Manager at Biosensors International Group, Ltd since March 2015, Jileen has consistently exceeded performance expectations in managing the CEO's calendar. Prior roles include Executive Assistant to the CEO at Electrolux Asia Pacific and Personal Assistant to the President/CEO at UOL Group Limited, where Jileen excelled in optimizing executive time through effective coordination and prioritization of tasks. Additionally, experience as Personal Assistant to Prof Kishore Mahbubani at the Lee Kuan Yew School of Public Policy and Office Manager at Hochtief AG highlights a strong foundation in high-stakes administrative support. Jileen holds a Private & Executive Secretary's Diploma from the London Chamber of Commerce & Industry.
This person is not in any teams
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.